Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Medtronic
Express Scripts
Colorcon
Merck
Boehringer Ingelheim
Moodys

Last Updated: May 21, 2022

CLINICAL TRIALS PROFILE FOR CORDARONE


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Cordarone

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00300495 ↗ Study of Amiodarone Given Before Lung Surgery to Prevent Atrial Fibrillation After Lung Resection Terminated Beth Israel Deaconess Medical Center Phase 3 2006-02-01 Atrial fibrillation is a very common complication of pulmonary resection. Patients who develop atrial fibrillation require additional treatment and are more likely to stay in the hospital for longer period of time increasing the costs associated with the operation. We propose a randomized controlled trial to see if oral amiodarone given for one week before surgery can prevent atrial fibrillation after pulmonary resection. We plan to evaluate the incidence of atrial fibrillation in patients who received preoperative amiodarone and compare them to the incidence of atrial fibrillation in patients who did not received preoperative amiodarone.
NCT00420953 ↗ Relative Bioavailability of PM101 IV and Cordarone IV Completed Prism Pharmaceuticals Phase 1 2006-12-18 Determine the relative bioavailability of PM101 I.V. and Cordarone I.V.
NCT00578617 ↗ Ablation vs Drug Therapy for Atrial Fibrillation - Pilot Trial Completed Abbott Medical Devices N/A 2006-09-01 The CABANA pilot study is designed to test the hypothesis that the treatment strategy of percutaneous left atrial catheter ablation for the purpose of the elimination of atrial fibrillation (AF) is superior to current state-of-the-art therapy with either rate control or anti-arrhythmic drugs for reducing AF recurrences at 1 year follow-up.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Cordarone

Condition Name

Condition Name for Cordarone
Intervention Trials
Atrial Fibrillation 12
Heart Failure 2
New Onset Atrial Fibrillation 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Cordarone
Intervention Trials
Atrial Fibrillation 17
Tachycardia, Ventricular 4
Tachycardia 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Cordarone

Trials by Country

Trials by Country for Cordarone
Location Trials
United States 62
Canada 13
Australia 4
France 4
Poland 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Cordarone
Location Trials
Pennsylvania 5
New York 4
Minnesota 4
Ohio 3
Maryland 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Cordarone

Clinical Trial Phase

Clinical Trial Phase for Cordarone
Clinical Trial Phase Trials
Phase 4 9
Phase 3 6
Phase 2 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Cordarone
Clinical Trial Phase Trials
Completed 10
Terminated 8
Unknown status 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Cordarone

Sponsor Name

Sponsor Name for Cordarone
Sponsor Trials
Abbott Medical Devices 3
St. Jude Medical 3
Mayo Clinic 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Cordarone
Sponsor Trials
Other 30
Industry 16
NIH 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKinsey
Mallinckrodt
Dow
Harvard Business School
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.